Company: RNAC
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001453687-25-000099
Chunk: 38

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 38
---
 incentive plans466,989 1,067,664 — —      Weighted-average common shares outstanding - diluted26,447,251 17,791,143 25,941,670 11,068,749 Net income (loss) per share:     Basic$0.51 $0.58 $(0.07)$(3.88)     Diluted$0.50 $0.54 $(0.07)$(3.88)The following table represents the potential dilutive shares of common stock excluded from the computation of the diluted net income (loss) per share allocable to common stockholders for all periods presented, as the effect would have been anti-dilutive:  Three Months EndedJune 30,Six Months EndedJune 30, 2025202420252024Common stock options and restricted stock units2,336,681 740,211 3,030,053 2,344,017 Warrants to purchase common stock692,523 975,132 692,523 975,132 Series A Preferred Stock4,026,346 5,544,719 4,026,346 5,544,719 Series B Preferred Stock437,927 — 437,927 — Total7,493,477 7,260,062 8,186,849 8,863,868 

7. Fair Value Measurements

The following tables present the Company’s assets and liabilities that are measured at fair value on a recurring basis as of June 30, 2025 and December 31, 2024 (in thousands):June 30, 2025TotalLevel 1Level 2Level 3Assets:     Money market funds (included in cash equivalents)$39,933 $39,933 $— $— Total assets$39,933 $39,933 $— $— Liabilities:     Warrant liabilities$1,364 $— $— $1,364      Contingent value right liability$352,100 $— $— $352,100 Total liabilities$353,464 $— $— $353,464  December 31, 2024TotalLevel 1Level 2Level 3Assets:     Money market funds (included in cash equivalents)$39,088 $39,